Astrazeneca Ab

Redx Pharma Limited

Jazz Pharmaceuticals Ireland Limited

Clifford David Jones

Craig Johnstone

Roger James

Michael Howard Block

Rodney Brian Hargreaves

Thomas Pesnot

Suzanne Saxon Bowker

Scott Boyd

Peter William Rodney Caulkett

Nicolas E S Guisot

Peter Bunyard

Gary Pitt

Liam Byrne

Steven Swallow

James Francis McCabe

Richard William Arthur Luke

William McCoull

Richard Andrew Ward

Darren McKerrecher

Andrew Hornby Dobson

Mark Andrew Graham

Jean-François Margathe

Andrew Belfield

Chiara Colletto

Patrick Ple

Andrew John Barker

Kevin Michael Foote

Bernard Christophe Barlaam

Zbigniew Stanley Matusiak

Darren Mckerrecher

David Michael Andrews

Clive Green

Maurice Raymond Finlay

Barry Raymond Hayter

Richard Armer

Nicolas Es Guisot

James Francis Mccabe

This invention relates to novel compounds and pharmaceutical compositions comprising. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.

Modulators of rho-associated protein kinase

The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method of using the compound of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.

Fused bicyclic RAF inhibitors and methods for use thereof

Modulators of Rho-associated protein kinase

This invention relates to novel compounds and pharmaceutical compositions comprising the same. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.

The present disclosure concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R, Rand Rhave any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cancer.

Chemical compounds

The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer. 

Pyridine compounds

The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R, R, R, n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).

Compounds effecting glucokinase

Compounds of formula (I): which possess cell-cycle inhibitory activity are described.

Imidazo[1,2-A]pyridine having anti-cell-proliferation activity

The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R, R, R, n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes.  The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).

A compound of the formula(I); wherein the substituents are as defined in the text for use in the production of an anti-angiogenic effect in a warm blooded animal such as man. The compounds are inhibitors Tie2 receptor tyrosine kinase (TEK). 

Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of Tie2

A compound of the Formula (I), wherein A together with the carbon atoms to which it is attached forms a fused 5-membered heteroaryl ring, wherein said heteroaryl ring contains 1 or 2 heteroatoms selected from O, N and S, and wherein the 5-membered ring containing G is linked to the ring formed by A in the meta position to the bridgehead carbon marked # in Formula (I): G is selected from O, S and NR; Z is selected from N and CR; Qis selected from optionally substituted aryl and heteroaryl, and the substituents Rto Rare as defined in the text for use in the production of an anti-angiogenic effect in a warm blooded animal such as man.

Condensed pyridines and pyrimidines with tie2 (TEK) activity

Growing community of inventors

Macclesfield, United Kingdom

Clifford David Jones